Literature DB >> 22510259

Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry.

Alain Beck1, Sarah Sanglier-Cianférani, Alain Van Dorsselaer.   

Abstract

This Feature will introduce the strategies of therapeutic antibodies (mAbs) in-depth characterization by mass spectrometry (MS) and discuss analytical comparison of biosimilar to originator mAbs, with the cases of trastuzumab and cetuximab. In addition, the structural and functional insights gained both by state-of-the art and emerging MS methods used for biobetters and next generation antibodies design and optimization will also be highlighted.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22510259     DOI： 10.1021/ac3002885

Source DB:  PubMed          Journal:  Anal Chem        ISSN： 0003-2700            Impact factor:   6.986


  70 in total

1.  Analysis of Monoclonal Antibody Sequence and Post-translational Modifications by Time-controlled Proteolysis and Tandem Mass Spectrometry.

Authors:  Lichao Zhang; A Michelle English; Dina L Bai; Scott A Ugrin; Jeffrey Shabanowitz; Mark M Ross; Donald F Hunt; Wei-Han Wang
Journal:  Mol Cell Proteomics       Date:  2015-11-29       Impact factor: 5.911

2.  Biosimilars in 3D: definition, development and differentiation.

Authors:  Ivo Abraham; Diana Sun; Alaa Bagalagel; Ahmed Altyar; Abdulaziz Mohammed; Soba Tharmarajah; Karen MacDonald
Journal:  Bioengineered       Date:  2013-05-16       Impact factor: 3.269

3.  Native MS and ECD Characterization of a Fab-Antigen Complex May Facilitate Crystallization for X-ray Diffraction.

Authors:  Ying Zhang; Weidong Cui; Aaron T Wecksler; Hao Zhang; Patricia Molina; Galahad Deperalta; Michael L Gross
Journal:  J Am Soc Mass Spectrom       Date:  2016-04-21       Impact factor: 3.109

Review 4.  Biosimilar: what it is not.

Authors:  Fernando de Mora
Journal:  Br J Clin Pharmacol       Date:  2015-06-04       Impact factor: 4.335

5.  Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.

Authors:  Rabah Gahoual; Michaël Biacchi; Johana Chicher; Lauriane Kuhn; Philippe Hammann; Alain Beck; Emmanuelle Leize-Wagner; Yannis N François
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 6.  Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.

Authors:  Jessica R McCombs; Shawn C Owen
Journal:  AAPS J       Date:  2015-01-22       Impact factor: 4.009

7.  Quantification of the IgG2/4 kappa Monoclonal Therapeutic Eculizumab from Serum Using Isotype Specific Affinity Purification and Microflow LC-ESI-Q-TOF Mass Spectrometry.

Authors:  Paula M Ladwig; David R Barnidge; Maria A V Willrich
Journal:  J Am Soc Mass Spectrom       Date:  2016-12-21       Impact factor: 3.109

8.  Complementary MS methods assist conformational characterization of antibodies with altered S-S bonding networks.

Authors:  Lisa M Jones; Hao Zhang; Weidong Cui; Sandeep Kumar; Justin B Sperry; James A Carroll; Michael L Gross
Journal:  J Am Soc Mass Spectrom       Date:  2013-03-13       Impact factor: 3.109

Review 9.  Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies.

Authors:  Hao Zhang; Weidong Cui; Michael L Gross
Journal:  FEBS Lett       Date:  2013-11-26       Impact factor: 4.124

10.  In-depth comparative characterization of hemoglobin glycation in normal and diabetic bloods by LC-MSMS.

Authors:  Shih-Hao Wang; Tzu-Fan Wang; Chih-Hsing Wu; Shu-Hui Chen
Journal:  J Am Soc Mass Spectrom       Date:  2014-02-28       Impact factor: 3.109
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.